Novome Biotechnologies is a South San Francisco-based company that specializes in engineering living medicines for chronic diseases. Their innovative approach involves building cell therapies that are precise, extensible, and symbiotic with the patient, aiming to achieve long-term health. Novome's platform, GEMMs (Genetically Engineered Microbial Medicines), focuses on colonizing the gut with engineered microbes to deliver targeted therapeutic activities for sustained and effective treatments.
With a strong emphasis on well-defined mechanisms of action and tunable treatment, Novome's therapies utilize highly-abundant gut microbes that are programmed with specific therapeutic functions. Their approach allows for convenient delivery through small, oral doses of a universal strain, making treatment safe, non-invasive, and tailored to specific conditions. Through their pipeline of programs, Novome aims to address a variety of diseases with clear etiology, including enteric hyperoxaluria, irritable bowel syndrome, and immuno-oncology.
Generated from the website